Currently enrolling at nine confirmed sites; Chicago, Richmond and Missouri are not enrolling
What is being offered: USDA-regulated EGFR/HER2 peptide-vaccine study led by Therajan. The current Canine Cancer Alliance status page identifies nine locations without a non-enrolling warning: Ventura, Edmonds, Pullman, Salt Lake City, Cleveland, Pittsburgh, Cincinnati, Phoenix and Stamford. Its same roster marks Chicago, Richmond and Columbia, Missouri as currently not enrolling. Stamford was separately confirmed on Veterinary Cancer Concierge Services' current trial page, which provides its intake pathway, eligibility materials and appointment location. Site-specific eligibility, scheduling and costs vary; MedVet restrictions apply only to its hospitals. Bridge also considers pulmonary carcinoma and high-grade mast cell tumor after records review, but those site-only indications are not mapped to the shared protocol record.
Who may qualify: Anticipated survival over 3 months; Standard of care therapy; Histology or long bone osa exception
May not qualify if: Other immunotherapy; Alternative therapy; Other clinical study
Costs / coverage: The investigational vaccine is provided at no charge; site visits, conventional treatment, administration and monitoring may be owner-paid. VCCS publishes a $695 charge for each vaccine appointment plus required testing. Confirm exact site-specific costs before enrollment.
Contact: Hope Veterinary Oncology — 805-626-6551; Bridge Animal Referral Center — 425-697-2272; Washington State University — 509-335-0711; MedVet Clinical Studies — clinicalstudies@medvet.com; MedVet Pittsburgh — oncology.pittsburgh@medvet.com; IVO — 602-841-0626; Veterinary Cancer Concierge Services — info@vetcancerconcierge.com.
Location
- Hope Veterinary Oncology, 1885 Knoll Drive, Ventura, CA 93003, Ventura, CA